Executive Summary / Key Takeaways

• Proprietary Formulation Platform as Economic Engine: Xeris's XeriSol and XeriJect technologies solve the fundamental clinical problem of unstable, difficult-to-administer injectable drugs, enabling ready-to-use formulations that command 85% gross margins while expanding addressable markets across multiple endocrine diseases.
• Recorlev as $1B Blockbuster in the Making: With 108% year-over-year patient growth and revenue surging 125% in Q3 2025, Recorlev is penetrating an underdiagnosed Cushing's syndrome market that management believes can support a billion-dollar product, validating the company's aggressive commercial expansion.
• Financial Inflection Proves Scalability: Q3 2025 marked Xeris's first-ever quarterly net income and positive operating cash flow ($8.6M), demonstrating that the business model can deliver both rapid growth and profitability simultaneously—a rare combination in commercial-stage biotech.
• Pipeline Optionality with XP-8121: The once-weekly levothyroxine program leverages the same XeriSol platform to target 3-5 million hypothyroidism patients who fail oral therapy, representing potential blockbuster expansion with Phase 3 initiation planned for second-half 2026.
• Execution Risk Amid Competitive Pressure: While the company has achieved EBITDA positivity, maintaining this while funding Recorlev's commercial doubling and XP-8121's clinical program through 2027 will test management's capital discipline against larger competitors like Corcept and Eli Lilly .

Setting the Scene: The Endocrine Specialist with a Formulation Edge

Xeris Biopharma Holdings, Inc., incorporated in 2005 and headquartered in Chicago, Illinois, has evolved from a technology-driven drug formulation company into a profitable commercial-stage pharmaceutical specialist focused on chronic endocrine and neurological diseases. The company's core identity centers on its proprietary XeriSol and XeriJect non-aqueous formulation platforms, which enable ready-to-use, room-temperature-stable injectable medicines that were previously uninjectable or required complex preparation. This technological foundation creates a durable economic moat: products that solve real clinical workflow problems while commanding premium pricing and superior gross margins.

The endocrine disease landscape presents both challenges and opportunities. Cushing's syndrome, a rare but serious disease caused by chronic elevated cortisol, remains underdiagnosed and undertreated, with surgery often ineffective or contraindicated. Primary Periodic Paralysis (PPP) affects a small patient population but has high unmet need. Severe hypoglycemia in diabetes impacts millions, yet an estimated 14 million at-risk patients still lack ready-to-use rescue medication. These niche markets are too small for large pharmaceutical giants to prioritize but large enough to support focused franchises—precisely where Xeris's specialized commercial infrastructure and formulation expertise create defensible positions.

Xeris operates in a competitive environment shaped by both branded and generic players. In Cushing's syndrome, Corcept Therapeutics (CORT) dominates with Korlym, generating $675 million in 2024 revenue with 40% growth. In glucagon, Eli Lilly's (LLY) Baqsimi nasal spray competes with Xeris's Gvoke injectable. Amphastar Pharmaceuticals (AMPH) pressures Keveyis with generic dichlorphenamide alternatives. Xeris's differentiation lies not in novel molecular entities alone, but in formulation innovation that improves administration, stability, and patient adherence—creating value beyond the active ingredient itself.

The 2021 acquisition of Strongbridge Biopharma proved transformative, providing Xeris with established commercial infrastructure and a second endocrine franchise. This deal integrated Strongbridge's equity plans and operational capabilities, setting the stage for the company's current multi-product strategy. The combined entity now leverages shared commercial resources across three marketed products while advancing a pipeline that utilizes the same core technology platform.

Technology, Products, and Strategic Differentiation

The XeriSol and XeriJect Platform Advantage

Xeris's proprietary formulation technologies represent the company's primary competitive moat. XeriSol creates non-aqueous, solubilized formulations of small molecules, while XeriJect produces highly concentrated, viscous formulations of large molecules. These platforms enable ready-to-use, room-temperature-stable injectables without preservatives—solving critical clinical pain points in emergency and chronic care settings. The economic implications are substantial: Gvoke's liquid-stable glucagon eliminates reconstitution errors, reducing training costs and improving emergency response times. Recorlev's oral formulation provides a cortisol synthesis inhibitor with fewer drug interactions than Corcept's Korlym, while maintaining convenient administration.

This technological edge translates directly into financial performance. Gross margins reached 85% in Q3 2025, driven by improved product mix favoring higher-margin Recorlev and reduced inventory write-offs. The platform approach creates manufacturing efficiencies: once the core formulation expertise is established, applying it to new molecules like XP-8121 requires incremental rather than duplicative investment. This scalability underpins management's confidence in maintaining profitability while funding growth.

Commercial Products: Three Franchises, One Platform

Recorlev: The Hypercortisolemia Growth Engine

Recorlev (levoketoconazole) treats endogenous hypercortisolemia in Cushing's syndrome patients for whom surgery is not an option. Q3 2025 revenue of $37 million represented 108.6% year-over-year growth, with the average number of patients on therapy growing 108% versus the prior year. This acceleration reflects both market expansion and Xeris's commercial execution. Management believes Recorlev is on pace to become a $1 billion product, a forecast grounded in the rapidly growing hypercortisolemia market driven by increased screening and diagnosis.

The strategic significance extends beyond revenue. Recorlev validates the XeriSol platform in a high-value chronic disease, demonstrating that formulation innovation can capture share against established competitors. The company's mid-2024 sales force expansion (50% increase) and Q3 2025's near-doubling of sales and patient support teams represent deliberate investments to capture this expanding market. These investments are already yielding returns: Q3 2025 marked the first quarter of net income, proving the commercial model's scalability.

Gvoke: Steady Market Expansion

Gvoke, a ready-to-use glucagon for severe hypoglycemia, delivered Q3 2025 revenue of $25.2 million, up 9.6% year-over-year. While growth appears modest compared to Recorlev, the strategic context matters deeply. Gvoke addresses a market where 14 million people on insulin or sulfonylureas remain unprotected by ready-to-use glucagon, despite medical guidelines recommending it. The March 2025 FDA approval of Gvoke VialDx for IV diagnostic use, partnered with American Regent for hospital commercialization, opens a new channel that leverages the same formulation technology.

Gvoke's reliability stems from its liquid-stable formulation—no mixing required, room-temperature storage, and dual-dose options. This convenience drives steady prescription growth and reinforces adherence to treatment guidelines. The product generates consistent cash flow to fund Recorlev's expansion and XP-8121 development, embodying the portfolio approach's financial discipline.

Keveyis: Durable Cash Generation

Keveyis, the first FDA-approved therapy for Primary Periodic Paralysis, generated $11.9 million in Q3 2025 revenue, a modest 2.1% decline year-over-year. While facing generic competition from Amphastar and Teva (TEVA), Keveyis demonstrates remarkable durability, ending 2024 with approximately the same number of patients as it started, despite a 13% revenue decline. This stability reflects the product's orphan drug status and strong patient support programs that maintain loyalty even in the face of lower-cost alternatives.

Keveyis serves as a cash-generating foundation that funds investment in higher-growth assets. Its performance proves Xeris's ability to manage mature products effectively, extracting value while minimizing erosion. The brand's ten-year anniversary in 2025 underscores its longevity and the company's expertise in rare disease commercialization.

Pipeline: XP-8121's Blockbuster Potential

XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, represents Xeris's most significant pipeline opportunity. The program leverages the same XeriSol platform, demonstrating technology reuse across therapeutic areas. Management estimates 3-5 million of the 20 million U.S. hypothyroidism patients are ideal candidates due to inability to achieve control with daily oral therapy, often from gastrointestinal absorption issues or drug interactions.

The Phase 2 study completed successfully in 2024, with Phase 3 initiation planned for second-half 2026. Management describes XP-8121 as having "blockbuster potential," a claim supported by the large addressable market and lack of innovation in hypothyroidism treatment for decades. The real clinical spend will peak in 2027, but the program benefits from leveraging existing commercial infrastructure built for Recorlev and Gvoke. This synergy reduces incremental investment requirements and accelerates potential time-to-market.

Financial Performance & Segment Dynamics

Revenue Growth Driven by Platform Execution

Total revenue reached $74.1 million in Q3 2025, with product revenue of $74.1 million representing the company's first profitable quarter. The nine-month revenue of $198.3 million puts Xeris on track to meet raised full-year guidance of $285-290 million, representing 42% growth at the midpoint. This acceleration from the initial $255-275 million range reflects exceptional commercial execution, particularly for Recorlev.

The segment mix shift drives both top-line growth and margin expansion. Recorlev's 125% nine-month revenue growth to $93.9 million transforms it from a promising launch to the company's largest product. Gvoke's steady 16.6% growth to $69.5 million provides reliable cash generation. Keveyis's 9.3% decline to $34.8 million reflects generic pressure but remains a profitable contributor. Royalty and contract revenue surged 93.9% to $6.5 million, boosted by milestone payments from the Gvoke VialDx partnership.

Margin Inflection Validates Scalability

Gross margin expanded to 85% in Q3 2025, a 10.9 percentage point improvement year-over-year, driven by favorable product mix toward higher-margin Recorlev and reduced Gvoke inventory write-offs. This margin level is exceptional for commercial-stage biotech and demonstrates the platform's economic leverage. For the nine-month period, gross margin improved 3.8 points to 81.8%, with the full-year 2024 margin at 82%.

Adjusted EBITDA reached $17.4 million in Q3 2025, a $20 million improvement versus Q3 2024, marking the third consecutive quarter of positive EBITDA. This profitability inflection proves that Xeris can scale revenue without proportional cost increases. SG&A expenses increased 9.3% year-over-year for the nine-month period, primarily from personnel investments in the Recorlev commercial organization starting in Q3 2024. However, revenue growth far outpaced expense growth, demonstrating operational leverage.

Cash Flow Generation and Balance Sheet Strength

Net cash provided by operating activities was $8.6 million for the nine months ended September 30, 2025, a dramatic reversal from $39 million used in the prior year period. This $47.6 million swing reflects higher product sales and improved working capital management. Net cash used in investing activities decreased to $363 thousand from $5.1 million, as the company reduced short-term investment purchases. Financing activities provided $11.7 million, driven by $20.2 million from stock award exercises offset by $9.3 million in stock repurchases for taxes.

As of September 30, 2025, Xeris had an accumulated deficit of $682.4 million but expects cash resources to sustain operations for at least 12 months. The company maintains no debt after converting $15.2 million of 2025 convertible notes into 4.98 million shares in March-April 2025. This deleveraging reduces interest expense and financial risk, providing flexibility to fund growth investments.

Outlook, Management Guidance, and Execution Risk

Ambitious but Achievable Guidance

Management raised full-year 2025 revenue guidance to $285-290 million, representing 42% growth at the midpoint, up from the initial $255-275 million range. This increase reflects confidence in sustained Recorlev momentum and Gvoke's steady expansion. The guidance assumes continued patient demand growth at or above second-half 2024 levels, which management describes as a "new trajectory" that isn't slowing.

The company expects a modest improvement in gross margin compared to 2024's 82%, driven by favorable product mix toward Recorlev. However, SG&A and R&D expenses will increase in the low-to-mid-teens percentage range, up from prior mid-to-high single-digit expectations. This reflects accelerated investment in Recorlev's commercial footprint expansion and XP-8121 Phase 3 readiness. Despite these incremental investments, management remains committed to maintaining positive adjusted EBITDA, a critical financial discipline that distinguishes Xeris from typical growth-stage biotechs.

Commercial Expansion ROI and Timing

The strategic decision to nearly double sales and patient support teams in Q3 2025 represents a calculated bet on Recorlev's market opportunity. These new reps will be fully productive starting January 2026, creating a step-up in SG&A spend that should generate revenue returns by mid-2026. The investment timing aligns with the hypercortisolemia market's rapid expansion, driven by new evidence linking sustained high cortisol to treatment-resistant diabetes and cardiovascular disease.

Management's confidence stems from Recorlev's differentiation as a cortisol synthesis inhibitor with fewer drug interactions than Corcept's Korlym. This clinical advantage, combined with expanded commercial reach, should enable Xeris to capture share in a market that benefits from increased screening and diagnosis. The risk lies in execution: if new reps fail to drive patient starts or if competitive pressure from Corcept's relacorilant launch intensifies, the ROI on this $10+ million annual investment could disappoint.

XP-8121: The 2026-2027 Spend Catalyst

XP-8121's Phase 3 initiation in second-half 2026 will trigger the "real bolus of clinical spend" that management expects to peak in 2027. While the program leverages existing XeriSol expertise and commercial infrastructure, Phase 3 trials for hypothyroidism will require significant investment in drug manufacturing, device validation, and patient enrollment. Management estimates 3-5 million ideal candidates in the U.S., suggesting a trial design that could be both large and expensive.

The strategic imperative is clear: XP-8121 represents Xeris's best opportunity to apply its platform technology to a market 10-20x larger than Cushing's syndrome. Success would transform the company from a rare disease specialist to a major endocrine player. However, the timing creates a financial tightrope: maintaining EBITDA positivity while funding this program will require flawless execution on Recorlev and Gvoke, as any revenue shortfall could force dilutive equity raises or debt issuance.

Risks and Asymmetries

Generic Erosion of Keveyis

Keveyis faces generic competition from Amphastar and Teva, with first generics launched in 2023. While the product has shown remarkable durability—maintaining patient count despite 13% revenue decline in 2024—this pressure will likely intensify. Generic manufacturers can undercut pricing by 50-70%, forcing Xeris to rely on patient support programs and orphan drug status to maintain share. The risk is that Keveyis's $50 million annual revenue base could erode faster than expected, reducing cash available for Recorlev and XP-8121 investment.

The mitigating factor is that Keveyis's ultra-rare PPP population benefits from specialized support that generics don't provide. Xeris's patient services help with diagnosis, prior authorization, and adherence—value-added services that create switching costs. However, if payers aggressively steer patients to generics, Keveyis could become a drag rather than a cash contributor.

Scale Disadvantage vs. Established Competitors

Corcept Therapeutics dominates the Cushing's market with Korlym, generating $675 million in 2024 revenue and guiding to $900-950 million in 2025. Corcept's established relationships, superior brand recognition, and lean operating model (90%+ gross margins) create formidable barriers. While Xeris's Recorlev is growing faster (108% vs. Corcept's ~40%), it remains a fraction of the market leader's size.

Similarly, Eli Lilly's Baqsimi benefits from massive commercial infrastructure and brand trust in diabetes care. Lilly can bundle glucagon with its GLP-1 franchise, creating convenience for prescribers. Xeris's Gvoke holds ~35% of retail prescriptions, but Lilly's scale could enable aggressive pricing or marketing that erodes this share. Xeris's smaller scale means higher relative customer acquisition costs and less negotiating power with payers.

Execution Risk on Platform Expansion

XP-8121's success is not guaranteed. While XeriSol has proven effective for glucagon and levoketoconazole, applying it to levothyroxine requires solving different stability and delivery challenges. The Phase 2 data must translate to Phase 3 success, and the device must deliver precise weekly doses across a wide therapeutic range. Failure would not only waste $50-100 million in clinical spend but also undermine the platform's credibility.

The asymmetry is substantial: success creates a potential $1-2 billion product in hypothyroidism, while failure limits Xeris to its current rare disease portfolio. Investors must weigh this binary outcome against the company's improving profitability. Management's planful approach—advancing drug manufacturing and device validation before Phase 3—reduces but doesn't eliminate this risk.

Valuation Context

At $6.51 per share, Xeris trades at a $1.08 billion market capitalization and $1.25 billion enterprise value. The stock's valuation metrics reflect a company at an inflection point from losses to profitability. With TTM revenue of $203 million, Xeris trades at 4.68x EV/Revenue, a discount to Corcept's 11.68x but a premium to Amphastar's 2.25x. This positioning seems appropriate given Xeris's faster growth (42% guided vs. Corcept's ~40%) and emerging profitability.

Key valuation metrics highlight the transformation:

• Gross Margin: 84.56% TTM, comparable to Corcept's 98% and Lilly's 83%, proving premium pricing power
• Operating Margin: 9.05% TTM, positive for the first time and trending toward Corcept's 4.92% (though Corcept's includes R&D for oncology expansion)
• Price-to-Sales: 4.06x, reasonable for a company growing 40%+ with improving margins
• Enterprise Value/EBITDA: 44.45x reflects early-stage profitability; this multiple should compress rapidly if EBITDA growth continues

The balance sheet provides strategic flexibility. With no debt after the 2025 convertible note conversion and positive operating cash flow, Xeris can fund growth internally. The accumulated deficit of $682 million is typical for biotech but now being offset by consistent profitability. Management's commitment to "not diluting shareholders" suggests they will prioritize debt or partnerships over equity raises, protecting against dilution.

Comparing Xeris to peers at similar growth stages suggests the market is still pricing in execution risk. Corcept's $9 billion valuation reflects established dominance and profitability, while Amphastar's $1.6 billion valuation reflects generic scale but slower growth. Xeris's $1.25 billion enterprise value appears reasonable if Recorlev can sustain 50%+ growth and XP-8121 reaches Phase 3 on schedule.

Conclusion

Xeris Biopharma has reached a rare inflection point where proprietary technology, commercial execution, and financial discipline converge. The XeriSol platform's ability to create ready-to-use, stable injectables has transformed a scientific capability into an economic moat, driving 85% gross margins and enabling rapid market penetration in Cushing's syndrome. Recorlev's 108% patient growth and the company's first profitable quarter prove this model is scalable, not just scientifically elegant.

The central thesis hinges on whether Xeris can maintain this momentum while funding two major strategic initiatives: doubling Recorlev's commercial footprint to capture a $1 billion market opportunity, and advancing XP-8121 into Phase 3 for hypothyroidism—a potential blockbuster that leverages the same platform. Management's commitment to EBITDA positivity during this investment phase is both ambitious and risky, as any stumble on execution or competitive response from Corcept or Lilly could strain resources.

For investors, the key variables are Recorlev's patient growth sustainability and XP-8121's clinical progress. If Recorlev can maintain 30-40% quarterly growth through 2026 and XP-8121 initiates Phase 3 on schedule, Xeris's valuation should re-rate toward Corcept's multiples as the market recognizes a durable, profitable endocrine franchise. If either falters, the company may face dilutive financing or strategic retrenchment. The platform's versatility provides downside protection, but execution will determine whether Xeris becomes a multi-product leader or remains a niche player.